Table 2.

Seroprotection and seroconversion rates of influenza A (H1N1) 2009 vaccine in patients with rheumatic disease and controls.

Seroprotection Rate (titer ≥ 1/40)Seroconversion Rate, % (95% CI)
NBefore Immunization, % (95% CI)After Immunization, % (95% CI)
Control9120.9 (12.6–29.3)95.6 (91.4–99.8)95.6 (91.4–99.8)
JARD23722.4 (17.1–27.7)81.4 (76.5–86.4)*74.3 (68.7–79.9)*
JSLE9920.2 (12.3–28.1)73.7 (65.0–82.4)*63.6 (54.1–73.1)*
JIA9320.4 (12.2–28.6)88.2 (81.6–94.8)82.8 (75.1–90.5)*
JDM1838.9 (16.4–61.4)83.3 (66.1–100.5)77.8 (58.6–97.0)*
JScl1127.3 (1.0–53.6)90.9 (73.9–107.9)90.9 (73.9–107.9)
Primary vasculitis1625.0 (13.8–46.2)81.3 (62.2–100.4)75 (53.8–96.2)*
  • * p < 0.05. JARD: juvenile autoimmune rheumatic diseases; JSLE: juvenile systemic lupus erythematosus; JIA: juvenile idiopathic arthritis; JDM: juvenile dermatomyositis; JScl: juvenile scleroderma.